The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CA184-240: A single-arm, open-label phase II study of vemurafenib followed by ipilimumab in patients with BRAF V600-mutated advanced melanoma (AM).
F. Stephen Hodi
Consultant or Advisory Role - Bristol-Myers Squibb (U)
Asim Amin
Consultant or Advisory Role - Bristol-Myers Squibb; Genentech
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Bristol-Myers Squibb; Genentech
Yvonne M. Saenger
Research Funding - Bristol-Myers Squibb
Other Remuneration - Bristol-Myers Squibb
Gregory K. Pennock
Honoraria - Bristol-Myers Squibb
Troy H. Guthrie
No relevant relationships to disclose
April K. Salama
Consultant or Advisory Role - Bristol-Myers Squibb (U); Roche/Genentech
Research Funding - Bristol-Myers Squibb
Lawrence E. Flaherty
Consultant or Advisory Role - Genomic Health; GlaxoSmithKline; Merck; Roche/Genentech; SMS Pharmaceuticals
Honoraria - Roche/Genentech
Henry B. Koon
Honoraria - Bristol-Myers Squibb; Genentech
Research Funding - Bristol-Myers Squibb; Genentech
David H. Lawson
Consultant or Advisory Role - Bristol-Myers Squibb; Roche/Genentech
Montaser F. Shaheen
No relevant relationships to disclose
Agnes Balogh
Employment or Leadership Position - Bristol-Myers Squibb
Cyril Konto
Employment or Leadership Position - Bristol-Myers Squibb
Stock Ownership - Bristol-Myers Squibb
Steven O'Day
Consultant or Advisory Role - Bristol-Myers Squibb (U); Roche (U)
Honoraria - Bristol-Myers Squibb; Roche
Research Funding - Bristol-Myers Squibb; Roche